Tina Moore

And they looked at different types of blood sugar-lowering drugs like metformin, GLP-1s, SGLT-2s, SGLT-2 inhibitors, I'm sorry. And they compared them all and then they sorted out what cardiovascular benefits were happening and dementia risk. So the mean age participant was about 65 years old, 64.4 years, I guess 64 years old. 35% were women and the average duration follow-up was 31.4 months.

And they looked at different types of blood sugar-lowering drugs like metformin, GLP-1s, SGLT-2s, SGLT-2 inhibitors, I'm sorry. And they compared them all and then they sorted out what cardiovascular benefits were happening and dementia risk. So the mean age participant was about 65 years old, 64.4 years, I guess 64 years old. 35% were women and the average duration follow-up was 31.4 months.

I will say that's a limitation of the study. They didn't follow up with them very long. And as we know, dementia takes decades to... So there's that. But overall, what they found, the key findings were that the cardioprotective glucose lowering therapies did not significantly reduce the risk of dementia or cognitive impairment overall. This is important and I want to reiterate what this means.

I will say that's a limitation of the study. They didn't follow up with them very long. And as we know, dementia takes decades to... So there's that. But overall, what they found, the key findings were that the cardioprotective glucose lowering therapies did not significantly reduce the risk of dementia or cognitive impairment overall. This is important and I want to reiterate what this means.

I will say that's a limitation of the study. They didn't follow up with them very long. And as we know, dementia takes decades to... So there's that. But overall, what they found, the key findings were that the cardioprotective glucose lowering therapies did not significantly reduce the risk of dementia or cognitive impairment overall. This is important and I want to reiterate what this means.

Whenever I talk about GLP-1s and their benefits, everybody wants to argue, well, wouldn't reducing your blood sugar, wouldn't optimizing your metabolic health, wouldn't weight loss already improve outcomes with X, Y, or Z? And yes, I would say yes. This showed that with other medications designed specifically to be cardioprotective and lower glucose, they did not see the dementia risk reduction.

Whenever I talk about GLP-1s and their benefits, everybody wants to argue, well, wouldn't reducing your blood sugar, wouldn't optimizing your metabolic health, wouldn't weight loss already improve outcomes with X, Y, or Z? And yes, I would say yes. This showed that with other medications designed specifically to be cardioprotective and lower glucose, they did not see the dementia risk reduction.

Whenever I talk about GLP-1s and their benefits, everybody wants to argue, well, wouldn't reducing your blood sugar, wouldn't optimizing your metabolic health, wouldn't weight loss already improve outcomes with X, Y, or Z? And yes, I would say yes. This showed that with other medications designed specifically to be cardioprotective and lower glucose, they did not see the dementia risk reduction.

So it's not as obvious as one would think it is. It's not just, oh, well, they lost weight, so of course their brain health improved. Or they lowered their blood sugar, so of course their brain health improved. Those things should indeed improve diabetes. brain health, but not like the GLP-1 did.

So it's not as obvious as one would think it is. It's not just, oh, well, they lost weight, so of course their brain health improved. Or they lowered their blood sugar, so of course their brain health improved. Those things should indeed improve diabetes. brain health, but not like the GLP-1 did.

So it's not as obvious as one would think it is. It's not just, oh, well, they lost weight, so of course their brain health improved. Or they lowered their blood sugar, so of course their brain health improved. Those things should indeed improve diabetes. brain health, but not like the GLP-1 did.

GLP-1 receptor agonists specifically were associated with a 45% relative reduction in dementia risk compared to controls. SGLT2 inhibitors showed no significant effect on dementia risk. Metformin had no eligible trials and the other drug, I cannot pronounce, pioglitazone showed no significant benefit.

GLP-1 receptor agonists specifically were associated with a 45% relative reduction in dementia risk compared to controls. SGLT2 inhibitors showed no significant effect on dementia risk. Metformin had no eligible trials and the other drug, I cannot pronounce, pioglitazone showed no significant benefit.

GLP-1 receptor agonists specifically were associated with a 45% relative reduction in dementia risk compared to controls. SGLT2 inhibitors showed no significant effect on dementia risk. Metformin had no eligible trials and the other drug, I cannot pronounce, pioglitazone showed no significant benefit.

Secondary findings, no statistically significant reduction in vascular dementia or Alzheimer's disease separately for any drug class. GLP-1 receptor agonist showed signals toward benefit across several cognitive measures, but no cognitive score improvements were consistently demonstrated across all included trials and no significant impact was seen on Lewy body dementia or frontotemporal dementia.

Secondary findings, no statistically significant reduction in vascular dementia or Alzheimer's disease separately for any drug class. GLP-1 receptor agonist showed signals toward benefit across several cognitive measures, but no cognitive score improvements were consistently demonstrated across all included trials and no significant impact was seen on Lewy body dementia or frontotemporal dementia.

Secondary findings, no statistically significant reduction in vascular dementia or Alzheimer's disease separately for any drug class. GLP-1 receptor agonist showed signals toward benefit across several cognitive measures, but no cognitive score improvements were consistently demonstrated across all included trials and no significant impact was seen on Lewy body dementia or frontotemporal dementia.

I get asked about that a lot, actually, about specific types of dementia. They had too few cases to really determine, so I'm not sure. The reason I got interested in GLP-1s, and for those who don't know what GLP-1 receptor agonists are, these are the drugs like Wegovy, Ozempic, Manjaro, Zepbound. These are all GLP-1 receptor agonists.

I get asked about that a lot, actually, about specific types of dementia. They had too few cases to really determine, so I'm not sure. The reason I got interested in GLP-1s, and for those who don't know what GLP-1 receptor agonists are, these are the drugs like Wegovy, Ozempic, Manjaro, Zepbound. These are all GLP-1 receptor agonists.

I get asked about that a lot, actually, about specific types of dementia. They had too few cases to really determine, so I'm not sure. The reason I got interested in GLP-1s, and for those who don't know what GLP-1 receptor agonists are, these are the drugs like Wegovy, Ozempic, Manjaro, Zepbound. These are all GLP-1 receptor agonists.